(Redirected from Mesalamine)
'Mesalazine' (
INN,
BAN), also known as 'Mesalamine' (
USAN) or '5-aminosalicylic acid' (5-ASA), is an
anti-inflammatory drug used to treat inflammation of the digestive tract (
Crohn's disease) and mild to moderate
ulcerative colitis. Mesalazine is a bowel-specific
aminosalicylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects.
As a derivative of
salicylic acid, 5-ASA is also an
antioxidant that traps
free radicals, which are potentially damaging by-products of metabolism.
5-ASA is considered the active
moiety of
sulfasalazine, which is metabolized to it.
Formulations
It is formulated for oral ingestion as tablets or granules, and for rectal administration as rectal
suppository, suspension or
enemas. It is sold under a variety of brand names (UK: Asacol, Ipocal, Pentasa & Salofalk. US: Canasa, Rowasa, Pentasa, Asacol and Lialda). The newest of these is Lialda, approved by the FDA in January 2007 for induction of remission in ulcerative colitis. Its main benefit is that it needs to be taken only once a day, which improves convenience and treatment compliance.
Dosing depends on the preparation used, in particular, slow-release tablets may have quite different drug delivery characteristics and are not interchangeable.
Preparations that lower stool pH (such as
lactulose, a laxative) will affect the binding of Mesalazine in the bowel and will therefore reduce its efficacy.
Side effects
Commonly:
★ Diarrhea
★ Nausea
★ Cramping
Uncommonly:
★ Headache
★ Exacerbation of the colitis
★ Hypersensitivity reactions (including rash,
urticaria,
interstitial nephritis and
lupus erythematosus-like syndrome)
★ Hair Loss
★
Interstitial nephritis
Rarely:
★ Acute
pancreatitis,
★
Hepatitis
★
Nephrotic syndrome
★ Blood disorders (including
agranulocytosis,
aplastic anaemia,
leukopenia,
neutropenia,
thrombocytopenia)
Mesalazine avoids the sulphonamide side effects of
Sulfasalazine (which contains additional (
sulfapyridine), but carries additional rare risks of:
★ Allergic lung reactions
★ Allergic
myocarditis
★
Methaemoglobinaemia
Monitoring
As a result of the small risks of kidney, liver and blood disorders, blood tests should be taken before and after starting treatment. Patients are advised to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise that occurs during treatment so that a
full blood count can be urgently taken.
References
★
British National Formulary ''45'' March 2003
★
, , , , Pharmaceutical Press, , ISBN 0-85369-550-4
External links
★
Optimal Dosing of 5-Aminosalicylic Acid: 5 Decades of Choosing Between Politicians
★
"Novel formulation increases efficacy of mesalamine for treating ulcerative colitis" Reuters article on Lialda/Mezavant trial success.